Nanotechnology-Based Approaches for the Management of Diabetes Mellitus: An Innovative Solution to Long-Lasting Challenges in Antidiabetic Drug Delivery

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2025 Jan 8

PMID 39771551

Authors

Shounak Sarkhel

Saikat Mollick Shuvo

Md Ahesan Ansari

Sourav Mondal

Pritam Kapat

Arindam Ghosh

Tanima Sarkar

Ranu Biswas

Leonard Ionut Atanase

Alexandru Carauleanu

Affiliations

Soon will be listed here.

Abstract

Diabetes is a widespread metabolic illness. Mismanagement of diabetes can lead to severe complications that tremendously impact patients' quality of life. The assimilation of nanotechnology in diabetes care holds the potential to revolutionize treatment paradigms, improve patient outcomes, and reduce the economic burden associated with this pervasive disease. This manuscript explores the multifaceted utilization of nanomaterials in diabetes care, emphasizing the unique features of nano-based medication delivery methods and smart drug delivery mechanisms. Additionally, this paper talks about research on nanocarrier-integrated oral, transdermal, and inhalable insulin delivery; dendrimer- and nanocarrier-coupled antisense oligonucleotide-driven gene therapy; the implementation of gold nanoparticles and quantum dots for glucose surveillance; and nucleic acid therapies. There are certain restrictions when using medication delivery methods that are commonly available to handle diabetes. In order to increase efficacy and safety, the rapidly developing science of nanotechnology is also being explored and employed in medical biology. Nanomaterials like liposomes, dendrimers, niosomes, polymeric and metallic nanocarriers, and solid lipid nanoparticles are among the nanocarriers that have been developed for better delivery of various oral hypoglycemic agents in comparison to conventional therapies. These nanocarriers provide great control over elevated blood glucose levels, making them one of the most intriguing and promising technologies available today. Furthermore, adding additional ligands to nanocarriers allows for more focused distribution while protecting the encapsulated hypoglycemic drugs.

References

Wong C, Al-Salami H, Dass C . Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment. J Control Release. 2017; 264:247-275. DOI: 10.1016/j.jconrel.2017.09.003. View

Ge X, Wei M, He S, Yuan W . Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery. Pharmaceutics. 2019; 11(2). PMC: 6410054. DOI: 10.3390/pharmaceutics11020055. View

Hunt N, Lockwood G, Heffernan S, Daymond J, Ngu M, Narayanan R . Oral nanotherapeutic formulation of insulin with reduced episodes of hypoglycaemia. Nat Nanotechnol. 2024; 19(4):534-544. PMC: 11026164. DOI: 10.1038/s41565-023-01565-2. View

Gu Z, Aimetti A, Wang Q, Dang T, Zhang Y, Veiseh O . Injectable nano-network for glucose-mediated insulin delivery. ACS Nano. 2013; 7(5):4194-201. PMC: 4107450. DOI: 10.1021/nn400630x. View

Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q . Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm. 2008; 356(1-2):333-44. DOI: 10.1016/j.ijpharm.2008.01.008. View

Bahman F, Greish K, Taurin S . Nanotechnology in Insulin Delivery for Management of Diabetes. Pharm Nanotechnol. 2019; 7(2):113-128. DOI: 10.2174/2211738507666190321110721. View

Pardakhty A, Varshosaz J, Rouholamini A . In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm. 2006; 328(2):130-41. DOI: 10.1016/j.ijpharm.2006.08.002. View

Tiwari P . Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update. J Diabetes Res. 2015; 2015:340838. PMC: 4530263. DOI: 10.1155/2015/340838. View

Kern N, Dong R, Douglas S, Vale R, Morrissey M . Tight nanoscale clustering of Fcγ receptors using DNA origami promotes phagocytosis. Elife. 2021; 10. PMC: 8175083. DOI: 10.7554/eLife.68311. View

10.

Aloke C, Egwu C, Aja P, Obasi N, Chukwu J, Akumadu B . Current Advances in the Management of Diabetes Mellitus. Biomedicines. 2022; 10(10). PMC: 9599361. DOI: 10.3390/biomedicines10102436. View

11.

Jini D, Sharmila S, Anitha A, Pandian M, Rajapaksha R . In vitro and in silico studies of silver nanoparticles (AgNPs) from Allium sativum against diabetes. Sci Rep. 2022; 12(1):22109. PMC: 9772310. DOI: 10.1038/s41598-022-24818-x. View

12.

Bajwa N, Mehra N, Jain K, Jain N . Pharmaceutical and biomedical applications of quantum dots. Artif Cells Nanomed Biotechnol. 2015; 44(3):758-68. DOI: 10.3109/21691401.2015.1052468. View

13.

Javed Ansari M, Anwer M, Jamil S, Al-Shdefat R, Ali B, Ahmad M . Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats. Drug Deliv. 2015; 23(6):1972-9. DOI: 10.3109/10717544.2015.1039666. View

14.

Zielinska A, Cano A, Andreani T, Martins-Gomes C, Silva A, Szalata M . Lipid-Drug Conjugates and Nanoparticles for the Cutaneous Delivery of Cannabidiol. Int J Mol Sci. 2022; 23(11). PMC: 9180973. DOI: 10.3390/ijms23116165. View

15.

Yan Y, Cai H, Yang M . The Application of Nanotechnology for the Diagnosis and Treatment of Endocrine Disorders: A Review of Current Trends, Toxicology and Future Perspective. Int J Nanomedicine. 2024; 19:9921-9942. PMC: 11439355. DOI: 10.2147/IJN.S477835. View

16.

Prasad P, Imam S, Aqil M, Sultana Y, Ali A . QbD-based carbopol transgel formulation: characterization, pharmacokinetic assessment and therapeutic efficacy in diabetes. Drug Deliv. 2014; 23(3):1057-66. DOI: 10.3109/10717544.2014.936536. View

17.

Cao X, Chen N, Li Y . Editorial: Beta cell function and diabetes remission. Front Endocrinol (Lausanne). 2024; 14:1298101. PMC: 10754965. DOI: 10.3389/fendo.2023.1298101. View

18.

Wong C, Al-Salami H, Dass C . Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus. Int J Pharm. 2018; 549(1-2):201-217. DOI: 10.1016/j.ijpharm.2018.07.041. View

19.

Ramasamy T, Ruttala H, Munusamy S, Chakraborty N, Kim J . Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics. J Control Release. 2022; 352:861-878. DOI: 10.1016/j.jconrel.2022.10.050. View

20.

Nqakala Z, Sibuyi N, Fadaka A, Meyer M, Onani M, Madiehe A . Advances in Nanotechnology towards Development of Silver Nanoparticle-Based Wound-Healing Agents. Int J Mol Sci. 2021; 22(20). PMC: 8539597. DOI: 10.3390/ijms222011272. View